Abeona Therapeutics, Inc.
(NASDAQ : ABEO)

( )
ABEO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.43%166.860.7%$1081.06m
PFEPfizer Inc. -1.38%48.590.9%$912.26m
LLYEli Lilly & Co. 0.04%316.961.1%$820.24m
MRKMerck & Co., Inc. 0.42%91.420.7%$782.30m
ABBVAbbVie, Inc. -0.04%141.391.9%$776.62m
BMYBristol-Myers Squibb Co. -0.55%74.151.0%$614.48m
SIGASIGA Technologies, Inc. -6.42%23.180.0%$439.36m
AZNAstraZeneca Plc 0.12%66.501.0%$365.07m
GBTGlobal Blood Therapeutics, Inc. 0.08%67.055.6%$352.06m
GSKGSK Plc -0.17%34.250.3%$285.96m
ALNYAlnylam Pharmaceuticals, Inc. 0.14%223.458.2%$270.68m
HZNPHorizon Therapeutics Plc -0.84%61.215.4%$225.68m
CCXIChemoCentryx, Inc. 0.43%51.002.9%$213.70m
KRTXKaruna Therapeutics, Inc. -0.08%261.010.0%$204.69m
VERUVeru, Inc. -21.47%18.680.0%$196.18m

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.